证券代码：832982 证券简称：锦波生物 公告编号：2025-157 二、股份协议转让过户情况 2025 年 9 月 15 日，中国证券登记结算有限责任公司出具了《证券过户登记 确认书》，上述协议转让事项已完成过户登记，过户数量为 5,753,267 股，过户 日期为 2025 年 9 月 12 日。 | 股东名称 | 本次权益变动前 | | 本次权益变动后 | | | --- | --- | --- | --- | --- | | | 持股数量（股） | 持股比例 | 持股数量（股） | 持股比例 | | 杨霞 | 67,766,972 | 58.89% | 62,013,705 | 53.89% | | 杭州久视 | 0 | 0% | 5,753,267 | 5.00% | 本次股份协议转让过户前后股份变化情况： 本次股份协议转让不会导致公司控股股东及实际控制人发生变更，不存在 损害公司及股东利益的情形，也不会影响公司的正常生产经营。 山西锦波生物医药股份有限公司 关于公司股东协议转让股份完成过户登记的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并 ...

Investment Rating - The report indicates a focus on the service consumption sector, with potential investment opportunities in companies listed on the Beijing Stock Exchange related to this industry [1]. Core Insights - The report highlights that several policy measures aimed at expanding service consumption are expected to be introduced in September 2025, which could significantly enhance the supply of high-quality services and stimulate new consumption scenarios [2][5][12]. - In 2024, China's service retail sales are projected to grow by 6.2% year-on-year, outpacing the growth of goods retail sales by 3 percentage points, indicating a robust demand for service consumption [6][8]. - The report identifies a substantial growth potential in service consumption in China, particularly in areas such as culture, leisure, tourism, and healthcare, as the country transitions towards a service-oriented economy [6][12]. Summary by Sections Policy Measures - The Ministry of Commerce plans to introduce new policies to boost service consumption, focusing on enhancing service supply and promoting investment in sectors like internet services, culture, and healthcare [2][5][12]. - Specific measures include encouraging foreign investment in sectors such as camping, homestays, and "Internet + healthcare" [2][5]. Market Performance - The median price change for companies in the service consumption sector on the Beijing Stock Exchange was -3.12% from September 8 to September 12, 2025, with 9 companies (23%) experiencing gains [15][16]. - The total market capitalization of the service consumption sector decreased from 132.17 billion to 128.91 billion yuan, with the median market capitalization dropping from 2.35 billion to 2.29 billion yuan [22][24]. Valuation Metrics - The median price-to-earnings (P/E) ratio for companies in the service consumption sector decreased from 57.9X to 52.5X [18][19]. - The broader consumer sector's median P/E ratio fell from 66.9X to 61.3X, indicating a general decline in valuations across the sector [28][29]. Company Analysis - The report lists several companies in the service consumption sector, including those in sports, tourism, healthcare, and education, highlighting their revenue and profit metrics for 2024 [13][14]. - Notable companies include Meizhigao, Guoyi Tendering, and Jinbo Biological, which showed significant price increases during the reporting period [25][26].

Market Overview - The medical beauty sector increased by 0.3% on September 15, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Individual Stock Performance - Huaxi Biological (688363) closed at 59.90, up 1.34%, with a trading volume of 56,000 shares and a transaction value of 334 million [1] - *ST Meigu (000615) closed at 3.13, up 0.32%, with a trading volume of 58,300 shares and a transaction value of 18.19 million [1] - Aimeike (300896) closed at 194.07, down 0.43%, with a trading volume of 28,800 shares and a transaction value of 561 million [1] - Jinbo Biological (832982) closed at 302.60, down 3.69%, with a trading volume of 15,400 shares and a transaction value of 471 million [1] Capital Flow Analysis - The medical beauty sector experienced a net outflow of 46.726 million from institutional investors, while retail investors saw a net inflow of 27.246 million [1] - The sector's overall capital flow indicates a mixed sentiment, with retail investors showing interest despite institutional outflows [1]

Group 1 - The core event involves a block trade of Jinbo Biological (stock code: 832982) on September 15, 2025, with a closing price of 302.6 yuan per share [1] - The block trade was executed at a price of 239 yuan per share, with a total volume of 4,200 shares, resulting in a transaction amount of 1.0038 million yuan, reflecting a discount of 21.02% [1] - The buying brokerage was Guojin Securities Co., Ltd., Shanghai Jing'an District Nanjing West Road Securities Business Department, while the selling brokerage was Guojin Securities Co., Ltd., Shenzhen Branch [1]

Core Viewpoint - The skincare and daily chemical industry in A-share listed companies has shown improvements in inventory levels for the first half of 2025, with only six out of fourteen selected companies experiencing an increase in inventory size [1][2]. Inventory Scale Analysis - In the first half of 2025, Jinbo Biological had the largest year-on-year increase in inventory, reaching 153 million yuan, a growth of 116.79% [2]. - Kesheng Co. also saw significant inventory growth, with a total of 628 million yuan, marking a 40.87% increase [2]. - Other companies with notable inventory increases include Marubi Biological (35.91%), Chuang'er Biological (34.02%), and Jiaheng Home Care (31.39%) [2]. Inventory Turnover Days - Among the fourteen selected companies, only five had inventory turnover days below 90 days, indicating efficient inventory management [2]. - Companies with inventory turnover days exceeding 180 days include Huaxi Biological (331.61 days), Jinbo Biological (280.81 days), Kesheng Co. (230.92 days), and Beitaini (195.78 days) [2][4]. - The overall inventory turnover efficiency in the industry is concerning, with six companies showing improvement while eight companies experienced longer turnover days [3]. Year-on-Year Changes in Inventory Turnover Days - Huaxi Biological's inventory turnover days increased by 13.34%, reaching 331.61 days [4]. - Jinbo Biological's turnover days rose by 15.66% to 280.81 days [4]. - Kesheng Co. saw a dramatic increase of 115.83% in turnover days, reaching 230.92 days [4]. - Other companies like Fushijia and Shanghai Jahwa also reported changes in turnover days, with Fushijia increasing by 31.52% [4].

证券代码：832982 证券简称：锦波生物 公告编号：2025-156 山西锦波生物医药股份有限公司 关于补选第四届董事会审计委员会委员的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 山西锦波生物医药股份有限公司（以下简称"公司"）于 2025 年 9 月 11 日 召开第四届董事会第十六次会议，审议通过了《关于补选第四届董事会审计委 员会委员的议案》，现将具体情况公告如下： 一、基本情况 鉴于公司原董事会审计委员会委员杨霞女士已当选公司总经理，不再满足 董事会审计委员会委员需为非高级管理人员董事的任职要求。为完善公司治理 结构，保障董事会审计委员会正常运行，根据《公司法》《公司章程》等相关规 定，拟补选李飞先生为公司第四届董事会审计委员会委员，任期自本次董事会 审议通过之日起至第四届董事会届满之日止。 2025 年 9 月 11 日 二、补选后的人员构成 补选后的审计委员会成员：阎丽明（召集人，独立董事）、梁桐栋（独立董 事）、李飞。 三、上述人员补选对公司的影响 本次董事会审计委员会委员的补 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-155 山西锦波生物医药股份有限公司 第四届董事会第十六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 9 月 11 日 2.会议召开地点：公司二楼会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2025 年 9 月 9 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：薛芳琴、兰小宾 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关 法律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 8 人，出席和授权出席董事 8 人。 董事王玲玲、阎丽明、梁桐栋、张金鑫因出差或外地办公以通讯方式参与表 决。 二、议案审议情况 （一）审议通过《关于补选第四届董事会审计委员会委员的议案》 1.议案内容： 4.提交股东会表决情 ...

Market Performance - The medical beauty sector rose by 2.11% on September 11, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3875.31, up 1.65%, while the Shenzhen Component Index closed at 12979.89, up 3.36% [1] Individual Stock Performance - Ai Meike (300896) closed at 201.00, with a gain of 3.10% and a trading volume of 46,300 shares, amounting to a transaction value of 909 million yuan [1] - Huaxi Biological (688363) closed at 59.51, up 0.86%, with a trading volume of 47,500 shares, totaling 279 million yuan [1] - ST Meigu (000615) remained unchanged at 3.14, with a trading volume of 55,800 shares, amounting to 17.45 million yuan [1] - Jinbo Biological (832982) closed at 307.80, down 0.03%, with a trading volume of 7,759.81 shares, totaling 237 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 35.23 million yuan from institutional investors, while retail investors experienced a net outflow of 45.10 million yuan [1] - Ai Meike had a net inflow of 35.43 million yuan from institutional investors, but a net outflow of 40.20 million yuan from retail investors [2] - Huaxi Biological experienced a net inflow of 1.46 million yuan from institutional investors, with a net outflow of 6.54 million yuan from retail investors [2] - ST Meigu had a net outflow of 1.66 million yuan from institutional investors, but a net inflow of 1.64 million yuan from retail investors [2]

Group 1 - The company announced a leadership change, with Jin Xuekun stepping down as General Manager and Yang Xia appointed as the new General Manager effective September 8, 2025 [3] - Yang Xia is the founder and actual controller of the company, holding 67.77 million shares, which accounts for 58.89% of the company's total equity [3] - The company also reported the resignation of independent director Zhang Jinxin and the transition of Li Fei to a representative director role [3] Group 2 - The company plans to raise up to 2 billion yuan by issuing no more than 7.1757 million shares to strategic investors, representing 6.24% of its pre-issue total equity [4] - Yang Xia signed a share transfer agreement to sell 5.7533 million shares to Hangzhou Jiushi at a price of 243.84 yuan per share, totaling 1.403 billion yuan [4] - Both strategic investors, Yang Xia and Hangzhou Jiushi, are ultimately controlled by Zhong Shanshan, who has invested 3.4 billion yuan into the company [4] Group 3 - The core business of the company focuses on the research, production, and sales of high-end implantable medical devices made from type A recombinant humanized collagen [5] - In the first half of 2025, the company achieved revenue of 859 million yuan, a year-on-year increase of 42.43%, with a gross margin of 90.68% and a net profit attributable to shareholders of 392 million yuan, up 26.65% year-on-year [5]

Group 1 - The core point of the article is the appointment of Yang Xia as the new General Manager of Jinbo Biological, effective from September 8, 2025, to July 31, 2027 [1] - Yang Xia has a background in academia and has held various positions within the company, including Chairman and Director of the Research Institute [1] - Yang Xia is the controlling shareholder of the company, holding 67,766,972 shares [1]